Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.61 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29782844 | 1.00 | PGR (0.61) | PGRTAS2R14ALDH1A1MAPTTDP1 | |
| SCHEMBL29931795 | 0.82 | RAB9A (0.49) | PGRTAS2R14ALDH1A1MAPTLMNA | |
| SCHEMBL29932025 | 0.82 | RAB9A (0.49) | PGRTAS2R14ALDH1A1MAPTLMNA | |
| SCHEMBL7163455 | 0.82 | RAB9A (0.63) | ALDH1A1MAPTLMNANPC1TNF | |
| SCHEMBL4616965 | 0.81 | NFE2L2 (0.53) | PGRTAS2R14LMNAKEAP1NFE2L2 | |
| SCHEMBL23536187 | 0.81 | RAB9A (0.47) | PGRTAS2R14ALDH1A1MAPTLMNA | |
| SCHEMBL12896230 | 0.81 | RAB9A (0.47) | PGRALDH1A1MAPTLMNANPC1 | |
| SCHEMBL3151230 | 0.80 | MTNR1B (0.56) | PGRALDH1A1LMNAKEAP1NFE2L2 | |
| SCHEMBL31352975 | 0.80 | MTNR1B (0.56) | PGRALDH1A1LMNAKEAP1NFE2L2 | |
| SCHEMBL29812140 | 0.79 | PGR (0.52) | PGRTAS2R14ALDH1A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709384-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | PMV PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2024238404-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-11938124-B2 | Combination therapy for treatment of cancer | PMV PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230024905-A1 | USES OF P53 X-RAY CO-CRYSTAL STRUCTURES | PMV PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4034104-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| US-9149465-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-8927551-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8765735-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20110028482-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938124-B2 | Combination therapy for treatment of cancer | TP53, KRAS, TP53BP1 | PGR 2359/4885TAS2R14 4291/4885ALDH1A1 2000/4885 |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | PGR 2633/4885TAS2R14 4562/4885ALDH1A1 1538/4885 |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | PGR 4655/4885TAS2R14 1115/4885ALDH1A1 2656/4885 |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, SCNN1B, TRPV1 | PGR 4715/4885TAS2R14 1275/4885ALDH1A1 2495/4885 |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | PGR 2544/4885TAS2R14 4537/4885ALDH1A1 1428/4885 |
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | PGR 441/4885TAS2R14 2945/4885ALDH1A1 1460/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | PGR 2158/4885TAS2R14 3072/4885ALDH1A1 1944/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | PGR 869/4885TAS2R14 2786/4885ALDH1A1 3910/4885 |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | PGR 2359/4885TAS2R14 4291/4885ALDH1A1 2000/4885 |
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | PGR 2633/4885TAS2R14 4562/4885ALDH1A1 1538/4885 |
| US-20230024905-A1 | USES OF P53 X-RAY CO-CRYSTAL STRUCTURES | TP53, TP53BP1, MDM2 | PGR 2562/4885TAS2R14 4102/4885ALDH1A1 3539/4885 |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | TP53, TP53BP1, KRAS | PGR 1501/4885TAS2R14 4054/4885ALDH1A1 1835/4885 |
| US-20110028482-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | PGR 3154/4885TAS2R14 2910/4885ALDH1A1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.